The Effects of Hepatogomax Enteral Formula on Systemic Inflammation, Caecum Short-Chain Fatty Acid Levels, and Liver Histopathology in Thioacetamide-Induced Rats.

IF 2.3 Q3 NUTRITION & DIETETICS

Journal of Nutrition and Metabolism Pub Date : 2023-09-14 eCollection Date: 2023-01-01 DOI:10.1155/2023/2313503

Hery D Purnomo, Refani A Kusuma, Elfrida Sianturi, Ryan F Haroen, Muchamad R Solichin, Choirun Nissa, Adriyan Pramono, Endang Mahati, Etika R Noer

{"title":"The Effects of Hepatogomax Enteral Formula on Systemic Inflammation, Caecum Short-Chain Fatty Acid Levels, and Liver Histopathology in Thioacetamide-Induced Rats.","authors":"Hery D Purnomo, Refani A Kusuma, Elfrida Sianturi, Ryan F Haroen, Muchamad R Solichin, Choirun Nissa, Adriyan Pramono, Endang Mahati, Etika R Noer","doi":"10.1155/2023/2313503","DOIUrl":null,"url":null,"abstract":"Liver damage characterized by fibrosis and necrosis can worsen the condition of liver disease. Liver disease is associated with impaired immune response and may affect short-chain fatty acid (SCFA) gut metabolites. Hepatogomax enteral formula was developed, which contains brain-chain amino acids (BCAAs) and middle-chain triglycerides (MCTs), which could repair liver tissue damage, improve the inflammatory status, and modulate SCFA in liver damage. The study aimed to determine the effect of hepatogomax on liver tissue repair, inflammation (TNF-α and IL-6), and SCFA levels in thioacetamide (TAA)-induced rats. The induction of TAA causes liver steatosis, increasing TNF-α and IL-6, and decreasing SCFA levels. Hepatogomax at a dose of 14.6 g/200 gBW significantly reduces TNF-α and IL-6 levels and increases SCFA levels (p < 0.05). The number of steatosis between groups P2 and P3 was lower as compared to a group of negative control [K2] (p < 0.05). Hepatogomax, in a dose-dependent manner, may repair liver tissue and improve inflammatory response and SCFA levels in TAA-induced rats.","PeriodicalId":16587,"journal":{"name":"Journal of Nutrition and Metabolism","volume":"2023 ","pages":"2313503"},"PeriodicalIF":2.3000,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513838/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nutrition and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/2313503","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Liver damage characterized by fibrosis and necrosis can worsen the condition of liver disease. Liver disease is associated with impaired immune response and may affect short-chain fatty acid (SCFA) gut metabolites. Hepatogomax enteral formula was developed, which contains brain-chain amino acids (BCAAs) and middle-chain triglycerides (MCTs), which could repair liver tissue damage, improve the inflammatory status, and modulate SCFA in liver damage. The study aimed to determine the effect of hepatogomax on liver tissue repair, inflammation (TNF-α and IL-6), and SCFA levels in thioacetamide (TAA)-induced rats. The induction of TAA causes liver steatosis, increasing TNF-α and IL-6, and decreasing SCFA levels. Hepatogomax at a dose of 14.6 g/200 gBW significantly reduces TNF-α and IL-6 levels and increases SCFA levels (p < 0.05). The number of steatosis between groups P2 and P3 was lower as compared to a group of negative control [K2] (p < 0.05). Hepatogomax, in a dose-dependent manner, may repair liver tissue and improve inflammatory response and SCFA levels in TAA-induced rats.

Abstract Image

查看原文本刊更多论文

肝癌肠溶方对硫代乙酰胺诱导大鼠全身炎症、盲肠短链脂肪酸水平和肝脏组织病理学的影响。

以纤维化和坏死为特征的肝损伤会使肝病病情恶化。肝病与免疫反应受损有关，并可能影响短链脂肪酸（SCFA）肠道代谢产物。开发了含有脑链氨基酸（BCAAs）和中链甘油三酯（MCTs）的肝癌肠内配方，可修复肝组织损伤，改善炎症状态，并调节肝损伤中的SCFA。本研究旨在确定肝癌对硫代乙酰胺（TAA）诱导的大鼠肝组织修复、炎症（TNF-α和IL-6）和SCFA水平的影响。TAA的诱导导致肝脏脂肪变性，增加TNF-α和IL-6，降低SCFA水平。14.6剂量的肝癌 g/200 gBW显著降低TNF-α和IL-6水平，增加SCFA水平（p p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Nutrition and Metabolism NUTRITION & DIETETICS-

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

17 weeks

期刊介绍： Journal of Nutrition and Metabolism is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering the broad and multidisciplinary field of human nutrition and metabolism. The journal welcomes submissions on studies related to obesity, diabetes, metabolic syndrome, molecular and cellular biology of nutrients, foods and dietary supplements, as well as macro- and micronutrients including vitamins and minerals.